These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26143528)

  • 1. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance).
    Boora GK; Kulkarni AA; Kanwar R; Beyerlein P; Qin R; Banck MS; Ruddy KJ; Pleticha J; Lynch CA; Behrens RJ; Züchner S; Loprinzi CL; Beutler AS
    J Neurol Sci; 2015 Oct; 357(1-2):35-40. PubMed ID: 26143528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy.
    Beutler AS; Kulkarni AA; Kanwar R; Klein CJ; Therneau TM; Qin R; Banck MS; Boora GK; Ruddy KJ; Wu Y; Smalley RL; Cunningham JM; Le-Lindqwister NA; Beyerlein P; Schroth GP; Windebank AJ; Züchner S; Loprinzi CL
    Ann Neurol; 2014 Nov; 76(5):727-37. PubMed ID: 25164601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance).
    Boora GK; Kanwar R; Kulkarni AA; Abyzov A; Sloan J; Ruddy KJ; Banck MS; Loprinzi CL; Beutler AS
    Cancer Med; 2016 Apr; 5(4):631-9. PubMed ID: 26763541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes.
    Le-Rademacher JG; Lopez CL; Kanwar R; Major-Elechi B; Abyzov A; Banck MS; Therneau TM; Sloan JA; Loprinzi CL; Beutler AS
    J Neurol Sci; 2020 Apr; 411():116687. PubMed ID: 32018185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of Charcot-Marie-Tooth disease gene mitofusin 2 expression in paclitaxel-induced mechanical allodynia in rats.
    Yamashita Y; Irie K; Kochi A; Kimura N; Hayashi T; Matsuo K; Myose T; Sano K; Nakano T; Takase Y; Nakamura Y; Satho T; Mishima K; Mishima K
    Neurosci Lett; 2017 Jul; 653():337-340. PubMed ID: 28587902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study.
    Adjei AA; Lopez CL; Schaid DJ; Sloan JA; Le-Rademacher JG; Loprinzi CL; Norman AD; Olson JE; Couch FJ; Beutler AS; Vachon CM; Ruddy KJ
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
    Chen Y; Fang F; Kidwell KM; Vangipuram K; Marcath LA; Gersch CL; Rae JM; Hayes DF; Lavoie Smith EM; Henry NL; Beutler AS; Hertz DL
    Pharmacogenomics; 2020 Aug; 21(12):841-851. PubMed ID: 32700628
    [No Abstract]   [Full Text] [Related]  

  • 8. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.
    Schneider BP; Lai D; Shen F; Jiang G; Radovich M; Li L; Gardner L; Miller KD; O'Neill A; Sparano JA; Xue G; Foroud T; Sledge GW
    Oncotarget; 2016 Dec; 7(50):82244-82253. PubMed ID: 27732968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
    Leal AD; Qin R; Atherton PJ; Haluska P; Behrens RJ; Tiber CH; Watanaboonyakhet P; Weiss M; Adams PT; Dockter TJ; Loprinzi CL;
    Cancer; 2014 Jun; 120(12):1890-7. PubMed ID: 24619793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.
    Sundar R; Jeyasekharan AD; Pang B; Soong RC; Kumarakulasinghe NB; Ow SG; Ho J; Lim JS; Tan DS; Wilder-Smith EP; Bandla A; Tan SS; Asuncion BR; Fazreen Z; Hoppe MM; Putti TC; Poh LM; Goh BC; Lee SC
    PLoS One; 2016; 11(10):e0164319. PubMed ID: 27716814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study.
    Salgado TM; Liu J; Reed HL; Quinn CS; Syverson JG; Le-Rademacher J; Lopez CL; Beutler AS; Loprinzi CL; Vangipuram K; Smith EML; Henry NL; Farris KB; Hertz DL
    Breast; 2020 Jun; 51():21-28. PubMed ID: 32193049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1.
    Kulkarni AA; Boora G; Kanwar R; Ruddy KJ; Banck MS; Le-Lindqwister N; Therneau TM; Loprinzi CL; Beutler AS
    Acta Oncol; 2015; 54(8):1227-9. PubMed ID: 25549536
    [No Abstract]   [Full Text] [Related]  

  • 13. Exploring clinical markers of Axon degeneration processes in Chemotherapy-induced peripheral neuropathy among young adults receiving vincristine or paclitaxel.
    Knoerl R; Mazzola E; Pazyra-Murphy M; Ryback B; Frazier AL; Freeman RL; Hammer M; LaCasce A; Ligibel J; Luskin MR; Berry DL; Segal RA
    BMC Neurol; 2024 Sep; 24(1):366. PubMed ID: 39342135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive biomarkers of chemotherapy-induced peripheral neuropathy: a review.
    Diaz PL; Furfari A; Wan BA; Lam H; Charames G; Drost L; Fefekos A; Ohearn S; Blake A; Asthana R; Chow E; DeAngelis C
    Biomark Med; 2018 Aug; 12(8):907-916. PubMed ID: 30044129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.
    Leandro-García LJ; Inglada-Pérez L; Pita G; Hjerpe E; Leskelä S; Jara C; Mielgo X; González-Neira A; Robledo M; Avall-Lundqvist E; Gréen H; Rodríguez-Antona C
    J Med Genet; 2013 Sep; 50(9):599-605. PubMed ID: 23776197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
    Mahmoudpour SH; Bandapalli OR; da Silva Filho MI; Campo C; Hemminki K; Goldschmidt H; Merz M; Försti A
    BMC Cancer; 2018 Aug; 18(1):820. PubMed ID: 30111286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
    Baldwin RM; Owzar K; Zembutsu H; Chhibber A; Kubo M; Jiang C; Watson D; Eclov RJ; Mefford J; McLeod HL; Friedman PN; Hudis CA; Winer EP; Jorgenson EM; Witte JS; Shulman LN; Nakamura Y; Ratain MJ; Kroetz DL
    Clin Cancer Res; 2012 Sep; 18(18):5099-109. PubMed ID: 22843789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ABCB1 polymorphisms in patients with Charcot-Marie-Tooth disease. A possible relationship with neurotoxicity due to cytostatic treatment].
    de la Haba-Rodríguez JR; Ortiz-Morales MJ; Gómez-España MA; Aranda Aguilar E
    Med Clin (Barc); 2012 Apr; 138(10):456-7. PubMed ID: 21982686
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetic epidemiology of Charcot-Marie-Tooth disease.
    Braathen GJ
    Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
    Le-Rademacher J; Kanwar R; Seisler D; Pachman DR; Qin R; Abyzov A; Ruddy KJ; Banck MS; Lavoie Smith EM; Dorsey SG; Aaronson NK; Sloan J; Loprinzi CL; Beutler AS
    Support Care Cancer; 2017 Nov; 25(11):3537-3544. PubMed ID: 28634656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.